Fundamental Analysis of REGULUS THERAPEUTICS INC(NASDAQ:RGLS) stock

Fundamental Rating

Overall RGLS gets a fundamental rating of 2 out of 10. We evaluated RGLS against 588 industry peers in the Biotechnology industry. RGLS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RGLS has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year RGLS has reported negative net income.

In the past year RGLS has reported a negative cash flow from operations.

RGLS had negative earnings in each of the past 5 years.

In the past 5 years RGLS always reported negative operating cash flow.

1.2 Ratios

RGLS has a worse Return On Assets (-97.67%) than 76.62% of its industry peers.

Looking at the Return On Equity, with a value of -141.76%, RGLS is doing worse than 63.99% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-97.67%
ROE	-141.76%
ROIC	N/A

ROA(3y)-66.31%

ROA(5y)-56.98%

ROE(3y)-92.46%

ROE(5y)-86.17%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RGLS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for RGLS has been increased compared to 1 year ago.

RGLS has more shares outstanding than it did 5 years ago.

RGLS has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -15.59, we must say that RGLS is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of RGLS (-15.59) is worse than 83.96% of its industry peers.

There is no outstanding debt for RGLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-15.59

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 3.31 indicates that RGLS has no problem at all paying its short term obligations.

With a Current ratio value of 3.31, RGLS is not doing good in the industry: 63.31% of the companies in the same industry are doing better.

A Quick Ratio of 3.31 indicates that RGLS has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 3.31, RGLS is doing worse than 61.77% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.31
Quick Ratio	3.31

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

RGLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.32%, which is quite good.

EPS 1Y (TTM)16.32%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q0%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 34.80% on average over the next years. This is a very strong growth

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y67.44%

EPS Next 2Y26.83%

EPS Next 3Y16.62%

EPS Next 5Y34.8%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RGLS. In the last year negative earnings were reported.

Also next year RGLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

RGLS's earnings are expected to grow with 16.62% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y26.83%

EPS Next 3Y16.62%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for RGLS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

REGULUS THERAPEUTICS INC

NASDAQ:RGLS (4/30/2024, 11:42:11 AM)

2.34

-0.18 (-7.14%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap153.20M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-97.67%
ROE	-141.76%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.31
Quick Ratio	3.31
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)16.32%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y67.44%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

REGULUS THERAPEUTICS INC (RGLS)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens